Avalo Therapeutics Grants Stock Options to New Employees

WAYNE, Pa., Sept. 04, 2026 /CourierPR/ -- Avalo Therapeutics, a clinical-stage biotechnology company focused on developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, has granted inducement equity awards to six new employees in accordance with Nasdaq Listing Rule 5635(c)(4). On September 2, 2026, the company awarded nonstatutory stock options to purchase an aggregate of 78,000 shares of common stock.

The Compensation Committee of Avalo's Board of Directors approved the inducement awards, which aim to attract and retain key talent. Each option has an exercise price of $19.34 per share, equivalent to the closing price of Avalo’s common stock on the grant date. The options will vest in stages: 25% of the underlying shares will vest on the one-year anniversary of each employee’s start date, with the remaining 75% vesting monthly over 36 months, contingent upon continued employment.

Abdakibart, Avalo’s lead anti-IL-1β monoclonal antibody drug candidate, is currently advancing into a phase 3 registrational program for hidradenitis suppurativa (HS), a chronic inflammatory skin condition affecting an estimated 1-4% of the global population. The company is also pursuing additional development opportunities in IL-1β-driven indications and developing AVTX-010, a long-acting next-generation anti-IL-1β mAb.

Forward-looking statements in this press release include plans, objectives, projections, expectations, and intentions with respect to drug development costs, timing of trials and trial results, and other risks, including reliance on investigators and patient enrollment, key personnel, regulatory matters, and economic and market uncertainties. Actual results may differ from those set forth in the forward-looking statements. Avalo Therapeutics expressly disclaims any obligations to update these forward-looking statements.